Avalo Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Avalo Therapeutics (Nasdaq: AVTX) will present at two investor conferences in March 2026: a TD Cowen Annual Healthcare Conference fireside chat on March 3, 2026 at 9:50 am ET and a Leerink Partners Global Healthcare Conference fireside chat on March 10, 2026 at 4:20 pm ET.

Live webcasts and archived replays will be available via the company's Investors "News / Events" page, with archived access for at least 30 days.

News Market Reaction – AVTX

+9.46%

24 alerts

+9.46% News Effect

+7.1% Peak in 5 hr 58 min

+$26M Valuation Impact

$305M Market Cap

1.2x Rel. Volume

On the day this news was published, AVTX gained 9.46%, reflecting a notable positive market reaction. Argus tracked a peak move of +7.1% during that session. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $26M to the company's valuation, bringing the market cap to $305M at that time.

Data tracked by StockTitan Argus on the day of publication.

WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:

TD Cowen Annual Healthcare Conference
Fireside Chat
March 3, 2026, at 9:50 am ET

Leerink Partners Global Healthcare Conference
Fireside Chat
March 10, 2026, at 4:20 pm ET

Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead asset, AVTX-009, is in a Phase 2 clinical trial for hidradenitis suppurativa (HS). We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. For more information about Avalo, please visit www.avalotx.com.

About AVTX-009 

AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a pro-inflammatory cytokine that plays a central role in the pathogenesis of a wide range of human diseases.¹ It activates immune cells that generate proinflammatory cytokines, including IL-6, TNF-α, and IL-17. Dysregulated IL-1β signaling is a major driver of inflammation, contributing to the progression of autoimmune disorders. IL-1β inhibition has proven effective in multiple immune-mediated inflammatory diseases.^1-3

References:¹Dinarello CA. Immunol Rev. 2018;281(1):8-27. ²Kany S et al. Int J Mol Sci. 2019;20(23):6008. ³Kimball AB et al. Presented at: American Academy of Dermatology; March 8-12, 2024; San Diego, CA.

For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com 
410-803-6793

or

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com 

FAQ

When will Avalo Therapeutics (AVTX) present at the TD Cowen Annual Healthcare Conference in 2026?

Avalo will present a fireside chat on March 3, 2026 at 9:50 am ET. According to Avalo, management will appear live and a webcast will be available through the Investors "News / Events" page for replay.

What is the date and time for Avalo Therapeutics (AVTX) at the Leerink Partners Global Healthcare Conference?

Avalo's fireside chat is scheduled for March 10, 2026 at 4:20 pm ET. According to Avalo, the event will be webcast and an archived replay will be posted on the company's investor site for at least 30 days.

Where can investors watch the Avalo Therapeutics (AVTX) webcasts and replays for March 2026 conferences?

Investors can view live webcasts and archived replays on Avalo's Investors "News / Events" page at https://ir.avalotx.com. According to Avalo, archived webcasts will remain available for replay for at least 30 days after the event.

Will Avalo Therapeutics (AVTX) provide archived replays of its March 2026 conference presentations?

Yes. Avalo will provide archived replays for at least 30 days after each presentation. According to Avalo, replays will be posted on the Investors "News / Events" page when available for on-demand viewing.

What topics will Avalo Therapeutics (AVTX) management likely cover during the March 2026 investor conference fireside chats?

Management will likely discuss the company's IL-1β clinical programs and strategy for immune-mediated inflammatory diseases. According to Avalo, the presentations will cover recent developments and investor updates relevant to clinical-stage activities.